This article has been updated with additional comment from the FDA regarding a Senate committee hearing in September, and a statement from the Personalized Medicine Coalition. 

NEW YORK (GenomeWeb) – Amid post-election uncertainty, the US Food and Drug Administration has decided to delay finalizing its draft guidance on regulating lab-developed tests, GenomeWeb has learned.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.